研究者データベース

鈴木 紗織(スズキ サオリ)
医学研究院 病理系部門 微生物学免疫学分野
助教

基本情報

所属

  • 医学研究院 病理系部門 微生物学免疫学分野

職名

  • 助教

学位

  • 博士(理学)(2016年03月 京都大学)

J-Global ID

研究分野

  • ライフサイエンス / ウイルス学

職歴

  • 2022年10月 - 現在 北海道大学 医学研究院 病理系部門 微生物学免疫学分野 助教
  • 2019年11月 - 2022年09月 プリンストン大学 ポスドク
  • 2019年05月 - 2019年10月 ペンシルベニア大学 ポスドク
  • 2016年04月 - 2019年04月 滋賀医科大学 病理学講座 特任助教
  • 2012年04月 - 2013年03月 京都大学霊長類研究所

所属学協会

  • 日本ウイルス学会   日本獣医学会   

研究活動情報

論文

  • Tomokazu Tamura, Jumpei Ito, Keiya Uriu, Jiri Zahradnik, Izumi Kida, Yuki Anraku, Hesham Nasser, Maya Shofa, Yoshitaka Oda, Spyros Lytras, Naganori Nao, Yukari Itakura, Sayaka Deguchi, Rigel Suzuki, Lei Wang, Mst Monira Begum, Shunsuke Kita, Hisano Yajima, Jiei Sasaki, Kaori Sasaki-Tabata, Ryo Shimizu, Masumi Tsuda, Yusuke Kosugi, Shigeru Fujita, Lin Pan, Daniel Sauter, Kumiko Yoshimatsu, Saori Suzuki, Hiroyuki Asakura, Mami Nagashima, Kenji Sadamasu, Kazuhisa Yoshimura, Yuki Yamamoto, Tetsuharu Nagamoto, Gideon Schreiber, Katsumi Maenaka, Takao Hashiguchi, Terumasa Ikeda, Takasuke Fukuhara, Akatsuki Saito, Shinya Tanaka, Keita Matsuno, Kazuo Takayama, Kei Sato
    Nature communications 14 1 2800 - 2800 2023年05月16日 [査読有り]
     
    In late 2022, SARS-CoV-2 Omicron subvariants have become highly diversified, and XBB is spreading rapidly around the world. Our phylogenetic analyses suggested that XBB emerged through the recombination of two cocirculating BA.2 lineages, BJ.1 and BM.1.1.1 (a progeny of BA.2.75), during the summer of 2022. XBB.1 is the variant most profoundly resistant to BA.2/5 breakthrough infection sera to date and is more fusogenic than BA.2.75. The recombination breakpoint is located in the receptor-binding domain of spike, and each region of the recombinant spike confers immune evasion and increases fusogenicity. We further provide the structural basis for the interaction between XBB.1 spike and human ACE2. Finally, the intrinsic pathogenicity of XBB.1 in male hamsters is comparable to or even lower than that of BA.2.75. Our multiscale investigation provides evidence suggesting that XBB is the first observed SARS-CoV-2 variant to increase its fitness through recombination rather than substitutions.
  • サルにおけるH5N1不活化全粒子ワクチン接種5年後の肺炎予防効果
    仲山 美沙子, 北川 直子, 石垣 宏仁, Nguyen Thanh Cong, 石田 英明, 鈴木 紗織, 小笠原 一誠, 伊藤 靖
    日本病理学会会誌 112 1 242 - 242 (一社)日本病理学会 2023年03月
  • Marumi Ohno, Masataka Sagata, Toshiki Sekiya, Naoki Nomura, Masashi Shingai, Masafumi Endo, Kazuhiko Kimachi, Saori Suzuki, Cong Thanh Nguyen, Misako Nakayama, Hirohito Ishigaki, Kazumasa Ogasawara, Yasushi Itoh, Yoichiro Kino, Hiroshi Kida
    Vaccine 41 3 787 - 794 2023年01月16日 
    Among inactivated influenza vaccines, the whole virus particle vaccine (WPV) elicits superior priming responses to split virus vaccine (SV) in efficiently inducing humoral and cellular immunity. However, there is concern for undesired adverse events such as fever for WPV due to its potent immunogenicity. Therefore, this study investigated the febrile response induced by subcutaneous injection with quadrivalent inactivated influenza vaccines of good manufacturing grade for pharmaceutical or investigational products in cynomolgus macaques. Body temperature was increased by 1 °C-2 °C for 6-12 h after WPV administration at the first vaccination but not at the second shot, whereas SV did not affect body temperature at both points. Given the potent priming ability of WPV, WPV-induced fever may be attributed to immune responses that uniquely occur during priming. Since WPV-induced fever was blunted by pretreatment with indomethacin (a cyclooxygenase inhibitor), the febrile response by WPV is considered to depend on the increase in prostaglandins synthesized by cyclooxygenase. In addition, WPV, but not SV, induced the elevation of type I interferons and monocyte chemotactic protein 1 in the plasma; these factors may be responsible for pyrogenicity caused by WPV, as they can increase prostaglandins in the brain. Notably, sufficient antibody responses were acquired by half the amount of WPV without causing fever, suggesting that excessive immune responses to trigger the febrile response is not required for acquired immunity induction. Thus, we propose that WPV with a reduced antigen dose should be evaluated for potential clinical usage, especially in naïve populations.
  • Saori Suzuki, Jacob B. Geri, Steve D. Knutson, Harris Bell-Temin, Tomokazu Tamura, David F. Fernández, Gabrielle H. Lovett, Nicholas A. Till, Brigitte L. Heller, Jinchao Guo, David W. C. MacMillan, Alexander Ploss
    Journal of the American Chemical Society 144 36 16604 - 16611 2022年09月14日 [査読有り]
     
    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the infectious agent of the COVID-19 pandemic, remains a global medical problem. Angiotensin-converting enzyme 2 (ACE2) was identified as the primary viral entry receptor, and transmembrane serine protease 2 primes the spike protein for membrane fusion. However, ACE2 expression is generally low and variable across tissues, suggesting that auxiliary receptors facilitate viral entry. Identifying these factors is critical for understanding SARS-Cov-2 pathophysiology and developing new countermeasures. However, profiling host-virus interactomes involves extensive genetic screening or complex computational predictions. Here, we leverage the photocatalytic proximity labeling platform mu Map to rapidly profile the spike interactome in human cells and identify eight novel candidate receptors. We systemically validate their functionality in SARS-CoV-2 pseudoviral uptake assays with both Wuhan and Delta spike variants and show that dual expression of ACE2 with either neuropilin-2, ephrin receptor A7, solute carrier family 6 member 15, or myelin and lymphocyte protein 2 significantly enhances viral uptake. Collectively, our data show that SARS-CoV-2 synergistically engages several host factors for cell entry and establishes mu Map as a powerful tool for rapidly interrogating host-virus interactomes.
  • Masanori Shiohara, Saori Suzuki, Shintaro Shichinohe, Hirohito Ishigaki, Misako Nakayama, Naoki Nomura, Masashi Shingai, Toshiki Sekiya, Marumi Ohno, Sayaka Iida, Naoko Kawai, Mamiko Kawahara, Junya Yamagishi, Kimihito Ito, Ryotarou Mitsumata, Tomio Ikeda, Kenji Motokawa, Tomoyoshi Sobue, Hiroshi Kida, Kazumasa Ogasawara, Yasushi Itoh
    Vaccine 40 30 4026 - 4037 2022年06月 [査読有り]
     
    The All-Japan Influenza Vaccine Study Group has been developing a more effective vaccine than the current split vaccines for seasonal influenza virus infection. In the present study, the efficacy of formalinand/or b-propiolactone-inactivated whole virus particle vaccines for seasonal influenza was compared to that of the current ether-treated split vaccines in a nonhuman primate model. The monovalent whole virus particle vaccines or split vaccines of influenza A virus (H1N1) and influenza B virus (Victoria lineage) were injected subcutaneously into naive cynomolgus macaques twice. The whole virus particle vaccines induced higher titers of neutralizing antibodies against H1N1 influenza A virus and influenza B virus in the plasma of macaques than did the split vaccines. At challenge with H1N1 influenza A virus or influenza B virus, the virus titers in nasal swabs and the increases in body temperatures were lower in the macaques immunized with the whole virus particle vaccine than in those immunized with the split vaccine. Repertoire analyses of immunoglobulin heavy chain genes demonstrated that the number of B lymphocyte subclones was increased in macaques after the 1st vaccination with the whole virus particle vaccine, but not with the split vaccine, indicating that the whole virus particle vaccine induced the activation of vaccine antigen-specific B-lymphocytes more vigorously than did the split vaccine at priming. Thus, the present findings suggest that the superior antibody induction ability of the whole virus particle vaccine as compared to the split vaccine is attributable to its stimulatory properties on the subclonal differentiation of antigen-specific B-lymphocytes. (c) 2022 Elsevier Ltd. All rights reserved.
  • Ruixue Wang, Saori Suzuki, Johnathan D. Guest, Brigitte Heller, Maricar Almeda, Alexander K. Andrianov, Alexander Marin, Roy A. Mariuzza, Zhen-Yong Keck, Steven K. H. Foung, Abdul S. Yunus, Brian G. Pierce, Eric A. Toth, Alexander Ploss, Thomas R. Fuerst
    Proceedings of the National Academy of Sciences 119 11 2022年03月15日 [査読有り]
     
    Significance Hepatitis C virus chronically infects approximately 1% of the world’s population, making an effective vaccine for hepatitis C virus a major unmet public health need. The membrane-associated E1E2 envelope glycoprotein has been used in clinical studies as a vaccine candidate. However, limited neutralization breadth and difficulty in producing large amounts of homogeneous membrane-associated E1E2 have hampered efforts to develop an E1E2-based vaccine. Our previous work described the design and biochemical validation of a native-like soluble secreted form of E1E2 (sE1E2). Here, we describe the immunogenic characterization of the sE1E2 complex. sE1E2 elicited broadly neutralizing antibodies in immunized mice, with increased neutralization breadth relative to the membrane-associated E1E2, thereby validating this platform as a promising model system for vaccine development.
  • Masashi Shingai, Naoki Nomura, Toshiki Sekiya, Marumi Ohno, Daisuke Fujikura, Chimuka Handabile, Ryosuke Omori, Yuki Ohara, Tomohiro Nishimura, Masafumi Endo, Kazuhiko Kimachi, Ryotarou Mitsumata, Tomio Ikeda, Hiroki Kitayama, Hironori Hatanaka, Tomoyoshi Sobue, Fumihito Muro, Saori Suzuki, Cong Thanh Nguyen, Hirohito Ishigaki, Misako Nakayama, Yuya Mori, Yasushi Itoh, Marios Koutsakos, Brendon Y Chua, Katherine Kedzierska, Lorena E Brown, David C Jackson, Kazumasa Ogasawara, Yoichiro Kino, Hiroshi Kida
    Vaccine 39 29 3940 - 3951 2021年06月 [査読有り]
     
    Current detergent or ether-disrupted split vaccines (SVs) for influenza do not always induce adequate immune responses, especially in young children. This contrasts with the whole virus particle vaccines (WPVs) originally used against influenza that were immunogenic in both adults and children but were replaced by SV in the 1970s due to concerns with reactogenicity. In this study, we re-evaluated the immunogenicity of WPV and SV, prepared from the same batch of purified influenza virus, in cynomolgus macaques and confirmed that WPV is superior to SV in priming potency. In addition, we compared the ability of WPV and SV to induce innate immune responses, including the maturation of dendritic cells (DCs) in vitro. WPV stimulated greater production of inflammatory cytokines and type-I interferon in immune cells from mice and macaques compared to SV. Since these innate responses are likely triggered by the activation of pattern recognition receptors (PRRs) by viral RNA, the quantity and quality of viral RNA in each vaccine were assessed. Although the quantity of viral RNA was similar in the two vaccines, the amount of viral RNA of a length that can be recognized by PRRs was over 100-fold greater in WPV than in SV. More importantly, 1000-fold more viral RNA was delivered to DCs by WPV than by SV when exposed to preparations containing the same amount of HA protein. Furthermore, WPV induced up regulation of the DC maturation marker CD86 on murine DCs, while SV did not. The present results suggest that the activation of antigen-presenting DCs, by PRR-recognizable viral RNA contained in WPV is responsible for the effective priming potency of WPV observed in naive mice and macaques. WPV is thus recommended as an alternative option for seasonal influenza vaccines, especially for children. (c) 2021 Elsevier Ltd. All rights reserved.
  • David W Sanders, Chanelle C Jumper, Paul J Ackerman, Dan Bracha, Anita Donlic, Hahn Kim, Devin Kenney, Ivan Castello-Serrano, Saori Suzuki, Tomokazu Tamura, Alexander H Tavares, Mohsan Saeed, Alex S Holehouse, Alexander Ploss, Ilya Levental, Florian Douam, Robert F Padera, Bruce D Levy, Clifford P Brangwynne
    eLife 10 2021年04月23日 [査読有り]
     
    Many enveloped viruses induce multinucleated cells (syncytia), reflective of membrane fusion events caused by the same machinery that underlies viral entry. These syncytia are thought to facilitate replication and evasion of the host immune response. Here, we report that co-culture of human cells expressing the receptor ACE2 with cells expressing SARS-CoV-2 spike, results in synapse-like intercellular contacts that initiate cell-cell fusion, producing syncytia resembling those we identify in lungs of COVID-19 patients. To assess the mechanism of spike/ACE2-driven membrane fusion, we developed a microscopy-based, cell-cell fusion assay to screen ~6000 drugs and >30 spike variants. Together with quantitative cell biology approaches, the screen reveals an essential role for biophysical aspects of the membrane, particularly cholesterol-rich regions, in spike-mediated fusion, which extends to replication-competent SARS-CoV-2 isolates. Our findings potentially provide a molecular basis for positive outcomes reported in COVID-19 patients taking statins and suggest new strategies for therapeutics targeting the membrane of SARS-CoV-2 and other fusogenic viruses.
  • Saori Suzuki, Cong Thanh Nguyen, Ayako Ogata-Nakahara, Akihiro Shibata, Hiroyuki Osaka, Hirohito Ishigaki, Masatoshi Okamatsu, Yoshihiro Sakoda, Hiroshi Kida, Kazumasa Ogasawara, Yasushi Itoh
    Antimicrobial Agents and Chemotherapy 65 3 2021年02月17日 [査読有り]
     
    H7N9 highly pathogenic avian influenza virus (HPAIV) infection in a human was first reported in 2017. A/duck/Japan/AQ-HE29-22/2017 (H7N9) (Dk/HE29-22), found in imported duck meat at an airport in Japan, possesses a hemagglutinin with a multibasic cleavage site, indicating high pathogenicity in chickens, as in the case of other H7 HPAIVs.
  • Marios Koutsakos, Toshiki Sekiya, Brendon Y Chua, Thi Hoang Oanh Nguyen, Adam K Wheatley, Jennifer A Juno, Marumi Ohno, Naoki Nomura, Yuki Ohara, Tomohiro Nishimura, Masafumi Endo, Saori Suzuki, Hirohito Ishigaki, Misako Nakayama, Cong T Nguyen, Yasushi Itoh, Masashi Shingai, Kazumasa Ogasawara, Yoichiro Kino, Stephen J Kent, David C Jackson, Lorena E Brown, Hiroshi Kida, Katherine Kedzierska
    Immunology & Cell Biology 99 1 97 - 106 2021年01月 [査読有り]
  • H7N9高病原性鳥インフルエンザウイルスに対するバロキサビルの有効性評価および免疫反応の解析
    鈴木 紗織, Nguyen Thanh Cong, 緒方 綾子[中原], 石垣 宏仁, 仲山 美沙子, 伊藤 靖
    日本獣医学会学術集会講演要旨集 163回 231 - 231 (公社)日本獣医学会 2020年10月
  • Keith A. Berggren, Saori Suzuki, Alexander Ploss
    International Journal of Molecular Sciences 21 11 3869 - 3869 2020年05月29日 [査読有り]
     
    The narrow range of species permissive to infection by hepatitis C virus (HCV) presents a unique challenge to the development of useful animal models for studying HCV, as well as host immune responses and development of chronic infection and disease. Following earlier studies in chimpanzees, several unique approaches have been pursued to develop useful animal models for research while avoiding the important ethical concerns and costs inherent in research with chimpanzees. Genetically related hepatotropic viruses that infect animals are being used as surrogates for HCV in research studies; chimeras of these surrogate viruses harboring specific regions of the HCV genome are being developed to improve their utility for vaccine testing. Concurrently, genetically humanized mice are being developed and continually advanced using human factors known to be involved in virus entry and replication. Further, xenotransplantation of human hepatocytes into mice allows for the direct study of HCV infection in human liver tissue in a small animal model. The current advances in each of these approaches are discussed in the present review.
  • Cong Thanh Nguyen, Saori Suzuki, Yasushi Itoh, Hirohito Ishigaki, Misako Nakayama, Kaori Hayashi, Keita Matsuno, Masatoshi Okamatsu, Yoshihiro Sakoda, Hiroshi Kida, Kazumasa Ogasawara
    Antimicrobial agents and chemotherapy 2020年04月13日 [査読有り][通常論文]
     
    Attention has been paid to H5N6 highly pathogenic avian influenza virus (HPAIV) because of its heavy burden on the poultry industry and human mortality. Since an influenza A virus carrying N6 neuraminidase (NA) has never spread in humans, the potential for H5N6 HPAIV to cause disease in humans and the efficacy of antiviral drugs against the virus need to be urgently assessed. We used non-human primates to elucidate the pathogenesis of H5N6 HPAIV as well as to determine the efficacy of antiviral drugs against the virus. H5N6 HPAIV infection led to high fever in cynomolgus macaques. The lung injury caused by the virus was severe with diffuse alveolar damage and neutrophil infiltration. In addition, an increase in IFN-α showed an inverse correlation with virus titers during the infection process. Oseltamivir was effective for reducing H5N6 HPAIV propagation, and continuous treatment with peramivir reduced virus propagation and severity of symptoms in the early stage. This study also showed the pathologically severe lung injury states in the cynomolgus macaques infected with H5N6 HPAIV, even in those that received early antiviral drug treatments, indicating the need for close monitoring and the need for further studies on the virus pathogenicity and new antiviral therapies.
  • Saori Suzuki, Shintaro Shichinohe, Yasushi Itoh, Misako Nakayama, Hirohito Ishigaki, Yuya Mori, Ayako Ogata-Nakahara, Cong Thanh Nguyen, Masatoshi Okamatsu, Yoshihiro Sakoda, Hiroshi Kida, Kazumasa Ogasawara
    Antiviral research 178 104790 - 104790 2020年04月06日 [査読有り][通常論文]
     
    Human cases of H7N9 influenza A virus infection have been increasing since 2013. The first choice of treatment for influenza is neuraminidase (NA) inhibitors (NAIs), but there is a concern that NAI-resistant viruses are selected in the presence of NAIs. In our previous study, an H7N9 virus carrying AA substitution of threonine (T) for isoleucine (I) at residue 222 in NA (NA222T, N2 numbering) and an H7N9 virus carrying AA substitution of lysine (K) for arginine (R) at residue 292 in NA (NA292K, N2 numbering) were found in different macaques that had been infected with A/Anhui/1/2013 (H7N9) and treated with NAIs. In the present study, the variant with NA292K showed not only resistance to NAIs but also lower replication activity in MDCK cells than did the virus with wild-type NA, whereas the variant with NA222T, which was less resistant to NAIs, showed replication activity similar to that of the wild-type virus. Next, we examined the pathogenicity of these H7N9 NAI-resistant viruses in macaques. The variants caused clinical signs similar to those caused by the wild-type virus with similar replication potency. However, the virus with NA292K was replaced within 7 days by that with NA292R (same as the wild-type) in nasal samples from macaques infected with the virus with NA292K, i.e. the so-called revertant (wild-type virus) became dominant in the population in the absence of an NAI. These results suggest that the clinical signs observed in macaques infected with the NA292K virus are caused by the NA292K virus and the NA292R virus and that the virus with NA292K may not replicate continuously in the upper respiratory tract of patients without treatment as effectively as the wild-type virus.
  • カニクイザルを用いたH7N9亜型高病原性鳥インフルエンザウイルスの病原性解析
    緒方 綾子, 鈴木 紗織, グエン・タンコン, 伊藤 靖, 石垣 宏仁, 仲山 美沙子, 小笠原 一誠
    日本病理学会会誌 109 1 506 - 506 (一社)日本病理学会 2020年03月
  • カニクイザルを用いたH7N9亜型高病原性鳥インフルエンザウイルスの病原性解析
    緒方 綾子, 鈴木 紗織, グエン・タンコン, 伊藤 靖, 石垣 宏仁, 仲山 美沙子, 小笠原 一誠
    日本病理学会会誌 109 1 506 - 506 (一社)日本病理学会 2020年03月
  • カニクイザルを用いたH5N6亜型高病原性鳥インフルエンザウイルスによる重症肺炎の解析
    伊藤 靖, Nguyen Thanh Cong, 鈴木 紗織, 石垣 宏仁, 仲山 美沙子, 小笠原 一誠
    日本病理学会会誌 108 1 285 - 285 (一社)日本病理学会 2019年04月
  • Toshiki Sekiya, Edin J Mifsud, Marumi Ohno, Naoki Nomura, Mayumi Sasada, Daisuke Fujikura, Takuji Daito, Masashi Shingai, Yuki Ohara, Tomohiro Nishimura, Masafumi Endo, Ryotarou Mitsumata, Tomio Ikeda, Hironori Hatanaka, Hiroki Kitayama, Kenji Motokawa, Tomoyoshi Sobue, Saori Suzuki, Yasushi Itoh, Lorena E Brown, Kazumasa Ogasawara, Yoichiro Kino, Hiroshi Kida
    Vaccine 37 15 2158 - 2166 2019年04月 [査読有り][通常論文]
  • Hiroshi Yokokawa, Atsunori Higashino, Saori Suzuki, Masaki Moriyama, Noriko Nakamura, Tomohiko Suzuki, Ryosuke Suzuki, Koji Ishii, Kouji Kobiyama, Ken J Ishii, Takaji Wakita, Hirofumi Akari, Takanobu Kato
    Gut 67 2 372 - 379 2018年02月 [査読有り][通常論文]
     
    OBJECTIVE: Although HCV is a major cause of chronic liver disease worldwide, there is currently no prophylactic vaccine for this virus. Thus, the development of an HCV vaccine that can induce both humoural and cellular immunity is urgently needed. To create an effective HCV vaccine, we evaluated neutralising antibody induction and cellular immune responses following the immunisation of a non-human primate model with cell culture-generated HCV (HCVcc). DESIGN: To accomplish this, 10 common marmosets were immunised with purified, inactivated HCVcc in combination with two different adjuvants: the classically used aluminum hydroxide (Alum) and the recently established adjuvant: CpG oligodeoxynucleotide (ODN) wrapped by schizophyllan (K3-SPG). RESULTS: The coadministration of HCVcc with K3-SPG efficiently induced immune responses against HCV, as demonstrated by the production of antibodies with specific neutralising activity against chimaeric HCVcc with structural proteins from multiple HCV genotypes (1a, 1b, 2a and 3a). The induction of cellular immunity was also demonstrated by the production of interferon-γ mRNA in spleen cells following stimulation with the HCV core protein. These changes were not observed following immunisation with HCVcc/Alum preparation. No vaccination-related abnormalities were detected in any of the immunised animals. CONCLUSIONS: The current preclinical study demonstrated that a vaccine included both HCVcc and K3-SPG induced humoural and cellular immunity in marmosets. Vaccination with this combination resulted in the production of antibodies exhibiting cross-neutralising activity against multiple HCV genotypes. Based on these findings, the vaccine created in this study represents a promising, potent and safe prophylactic option against HCV.
  • Saori Suzuki, Ken-ichi Mori, Atsunori Higashino, Yuki Iwasaki, Yasuhiro Yasutomi, Noboru Maki, Hirofumi Akari
    MICROBIOLOGY AND IMMUNOLOGY 60 1 26 - 34 2016年01月 [査読有り][通常論文]
     
    The development of effective hepatitis C virus (HCV) vaccines is essential for the prevention of further HCV dissemination, especially in developing countries. Therefore the aim of this study is to establish a feasible and immunocompetent surrogate animal model of HCV infection that will help in evaluation of the protective efficacy of newly developing HCV vaccine candidates. To circumvent the narrow host range of HCV, an HCV genotype 1b-based chimeric clone carrying E1, E2 and p6 regions from GB virus B (GBV-B), which is closely related to HCV, was generated. The chimera between HCV and GBV-B, named HCV/G, replicated more efficiently as compared with the HCV clone in primary marmoset hepatocytes. Furthermore, it was found that the chimera persistently replicated in a tamarin for more than 2 years after intrahepatic inoculation of the chimeric RNA. Although relatively low (<200 copies/mL), the viral RNA loads in plasma were detectable intermittently during the observation period. Of note, the chimeric RNA was found in the pellet fraction obtained by ultracentrifugation of the plasma at 73 weeks, indicating production of the chimeric virus. Our results will help establish a novel non-human primate model for HCV infection on the basis of the HCV/G chimera in the major framework of the HCV genome.
  • Saori Suzuki, Satoru Konnai, Tomohiro Okagawa, Ryoyo Ikebuchi, Asami Nishimori, Junko Kohara, Claro N. Mingala, Shiro Murata, Kazuhiko Ohashi
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY 163 3-4 115 - 124 2015年02月 [査読有り][通常論文]
     
    Regulatory T cells (Tregs) play a critical role in the maintenance of the host's immune system. Tregs, particularly CD4(+)CD25(+)Foxp3(+) T cells, have been reported to be involved in the immune evasion mechanism of tumors and several pathogens that cause chronic infections. Recent studies showed that a Treg-associated marker, cytotoxic T-lymphocyte antigen 4 (CTLA-4), is closely associated with the progression of several diseases. We recently reported that the proportion of Foxp3(+)CD4(+) cells was positively correlated with the number of lymphocytes, virus titer, and virus load but inversely correlated with IFN-gamma expression in cattle infected with bovine leukemia virus (BLV), which causes chronic infection and lymphoma in its host. Here the kinetics of CfLA-4(+) cells were analyzed in BLV-infected cattle. CTLA-4 mRNA was predominantly expressed in CD4+ T cells in BLV-infected cattle, and the expression was positively correlated with Foxp3 mRNA expression. To test for differences in the protein expression level of CTLA-4, we measured the proportion of CTLA-4-expressing cells by flow cytometry. In cattle with persistent lymphocytosis (PL), mean fluorescence intensities (MFIs) of CTLA-4 on CD4(+) and CD25(+) T cells were significantly increased compared with that in control and aleukemic (AL) cattle. The percentage of CTLA-4(+) cells in the CD4(+) T cell subpopulation was positively correlated with TGF-beta mRNA expression, suggesting that CD4(+)CTLA-4(+) T cells have a potentially immunosuppressive function in BLV infection. In the limited number of cattle that were tested, the anti-CTLA-4 antibody enhanced the expression of CD69, IL-2, and IFN-gamma mRNA in anti-programmed death ligand 1 (PD-L1) antibody-treated peripheral blood mononuclear cells from BLV-infected cattle. Together with previous findings, the present results indicate that Tregs may be involved in the inhibition of T cell function during BLV infection. (C) 2014 Elsevier B.V. All rights reserved.
  • Yasumitsu Fujie, Noemi Fusaki, Tomohiko Katayama, Makoto Hamasaki, Yumi Soejima, Minami Soga, Hiroshi Ban, Mamoru Hasegawa, Satoshi Yamashita, Shigemi Kimura, Saori Suzuki, Tetsuro Matsuzawa, Hirofumi Akari, Takumi Era
    PLOS ONE 9 12 e113052  2014年12月 [査読有り][通常論文]
     
    Induced pluripotent stem cells (iPSCs) are potentially valuable cell sources for disease models and future therapeutic applications; however, inefficient generation and the presence of integrated transgenes remain as problems limiting their current use. Here, we developed a new Sendai virus vector, TS12KOS, which has improved efficiency, does not integrate into the cellular DNA, and can be easily eliminated. TS12KOS carries KLF4, OCT3/4, and SOX2 in a single vector and can easily generate iPSCs from human blood cells. Using TS12KOS, we established iPSC lines from chimpanzee blood, and used DNA array analysis to show that the global gene-expression pattern of chimpanzee iPSCs is similar to those of human embryonic stem cell and iPSC lines. These results demonstrated that our new vector is useful for generating iPSCs from the blood cells of both human and chimpanzee. In addition, the chimpanzee iPSCs are expected to facilitate unique studies into human physiology and disease.
  • HIV-1感染霊長類モデルの樹立に向けた、 Macaca属サルにおけるTRIM5遺伝子の多様性に関する研究
    齊藤暁, 河野健, 川本芳, 東濃篤徳, 鈴木紗織, 吉田友教, 鳥居隆三, 保富康宏, 塩田達雄, 中山英美, 明里宏文
    日本エイズ学会誌 16 1 28 - 36 2014年 [査読無し][招待有り]
  • Saori Suzuki, Satoru Konnai, Tomohiro Okagawa, Ryoyo Ikebuchi, Tatsuya Shirai, Yuji Sunden, Claro N. Mingala, Shiro Murata, Kazuhiko Ohashi
    Microbiology and Immunology 57 8 600 - 604 2013年08月 [査読有り][通常論文]
     
    In the present study, we monitored Foxp3+ T cells in bovine leukemia virus (BLV)-infected cattle. By flow cytometric analysis, the proportion of Foxp3+CD4+ cells from persistent lymphocytotic cattle was significantly increased compared to control and AL cattle. Interestingly, the proportion of Foxp3+CD4+ cells correlated positively with the increased number of lymphocytes, virus titer and virus load, whereas it inversely correlated with IFN-γ mRNA expression, suggesting that Foxp3+CD4+ T cells in cattle have a potentially immunosuppressive function. Further studies are necessary to elucidate the detailed mechanism behind the increased Treg during BLV infection. © 2013 The Societies and Wiley Publishing Asia Pty Ltd.
  • Tomoyuki Yoshida, Saori Suzuki, Yuki Iwasaki, Akihisa Kaneko, Akatsuki Saito, Yuki Enomoto, Atsunori Higashino, Akino Watanabe, Juri Suzuki, Kenichi Inoue, Teiko Kuroda, Masahiko Takada, Ryoji Ito, Mamoru Ito, Hirofumi Akari
    IMMUNOLOGY LETTERS 154 1-2 12 - 17 2013年07月 [査読有り][通常論文]
     
    In order to directly demonstrate the roles of CD8(+) T lymphocytes in non-human primates, in vivo depletion of the CD8(+) T cells by administration of a CD8-specific monoclonal antibody (mAb) is one of the crucial techniques. Recently, the common marmoset (Callithrix jacchus), which is classified as a New World monkey, has been shown useful as an experimental animal model for various human diseases such as multiple sclerosis, Parkinson's disease and a number of infectious diseases. Here we show that an anti-marmoset CD8 mAb 6F10, which we have recently established, efficiently depletes the marmoset CD8+ T lymphocytes in vivo, i.e., the administration of 6F10 induces drastic and specific reduction in the ratio of the CD8(+) T cell subset for at least three weeks or longer. Our finding will help understand the pivotal role of CD8(+) T cells in vivo in the control of human diseases. (C) 2013 Elsevier B.V. All rights reserved.
  • Suzuki S, Konnai S, Okagawa T, Ikebuchi R, Shirai T, Sunden Y, Mingala CN, Murata S, Ohashi K
    Microbiology and immunology 2013年06月 [査読有り][通常論文]
  • Satoru Konnai, Saori Suzuki, Tatsuya Shirai, Ryoyo Ikebuchi, Tomohiro Okagawa, Yuji Sunden, Claro N. Mingala, Misao Onuma, Shiro Murata, Kazuhiko Ohashi
    COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES 36 1 63 - 69 2013年01月 [査読有り][通常論文]
     
    An immunoinhibitory receptor, lymphocyte activation gene-3 (LAG-3), which is mainly expressed in T-cells, is involved in the immune evasion of several pathogens causing chronic infections and tumors. However, unlike human or mouse LAG-3, no functional analysis of LAG-3 has been reported in domestic animals. Thus, in this study, bovine LAG-3 expression was analyzed in bovine leukemia virus (BLV)-infected cattle. In persistent lymphocytotic (PL) cattle, the numbers of LAG-3(+)CD4(+) cells and LAG-3(+)CD8(+) cells were conserved whilst the number of MHC class II+ cells was remarkably higher than in the control animals. In contrast, the mean fluorescence intensity (MFI) for LAG-3 on PBMCs from PL cattle was significantly increased compared to control and asymptomatic (AL) cattle. Specifically, the LAG-3 expression level was significantly increased in both CD4(+) and CD8(+) T cells from PL cattle. LAG-3 expression correlated positively with increased numbers of lymphocytes and MHC class II+ cells in infected animals. Preliminary results from PD-L1 and LAG-3 blockade assay revealed that IFN-gamma and IL-2 expressions were significantly up-regulated by addition of anti- PD-L1 and LAG-3 antibodies in PBMCs from PL cattle. These findings suggest that LAG-3 might be involved in the inhibition of T-cell function through its binding and signaling on MHC class II molecule during BLV infection. (c) 2012 Elsevier Ltd. All rights reserved.
  • Tomohiro Okagawa, Satoru Konnai, Hirohisa Mekata, Naftaly Githaka, Saori Suzuki, Edward Kariuki, Francis Gakuya, Esther Kanduma, Tatsuya Shirai, Ryoyo Ikebuchi, Yoshinori Ikenaka, Mayumi Ishizuka, Shiro Murata, Kazuhiko Ohashi
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY 148 3-4 373 - 379 2012年08月 [査読有り][通常論文]
     
    Theileria parva (T. parva) causes East Coast fever (ECF), which is of huge economic importance to Eastern and Southern African countries. In a previous bovine model, inflammatory cytokines were closely associated with disease progression in animals experimentally infected with T. parva. The African Cape buffalo (Syncerus coffer), the natural reservoir for T. parva, is completely resistant to ECF despite a persistently high parasitaemia following infection with T. parva. Characterizing basic immunological interactions in the host is critical to understanding the mechanism underlying disease resistance in the African Cape buffalo. In this study, the expression level of several cytokines was analyzed in T. parva-infected buffaloes. There were no significant differences in the expression profiles of inflammatory cytokines between the infected and uninfected animals despite a remarkably high parasitaemia in the former. However, the expression level of IL-10 was significantly upregulated in the infected animals. These results indicate a correlation between diminished inflammatory cytokines response and disease resistance in the buffalo. (c) 2012 Elsevier B.V. All rights reserved.
  • Tomohiro Okagawa, Satoru Konnai, Ryoyo Ikebuchi, Saori Suzuki, Tatsuya Shirai, Yuji Sunden, Misao Onuma, Shiro Murata, Kazuhiko Ohashi
    VETERINARY RESEARCH 43 45  2012年05月 [査読有り][通常論文]
     
    The immunoinhibitory receptor T cell immunoglobulin domain and mucin domain-3 (Tim-3) and its ligand, galectin-9 (Gal-9), are involved in the immune evasion mechanisms for several pathogens causing chronic infections. However, there is no report concerning the role of Tim-3 in diseases of domestic animals. In this study, cDNA encoding for bovine Tim-3 and Gal-9 were cloned and sequenced, and their expression and role in immune reactivation were analyzed in bovine leukemia virus (BLV)-infected cattle. Predicted amino acid sequences of Tim-3 and Gal-9 shared high homologies with human and mouse homologues. Functional domains, including tyrosine kinase phosphorylation motif in the intracellular domain of Tim-3 were highly conserved among cattle and other species. Quantitative real-time PCR analysis showed that bovine Tim-3 mRNA is mainly expressed in T cells such as CD4(+) and CD8(+) cells, while Gal-9 mRNA is mainly expressed in monocyte and T cells. Tim-3 mRNA expression in CD4(+) and CD8(+) cells was upregulated during disease progression of BLV infection. Interestingly, expression levels for Tim-3 and Gal-9 correlated positively with viral load in infected cattle. Furthermore, Tim-3 expression level closely correlated with up-regulation of IL-10 in infected cattle. The expression of IFN-gamma and IL-2 mRNA was upregulated when PBMC from BLV-infected cattle were cultured with Cos-7 cells expressing Tim-3 to inhibit the Tim-3/Gal-9 pathway. Moreover, combined blockade of the Tim-3/Gal-9 and PD-1/PD-L1 pathways significantly promoted IFN-gamma mRNA expression compared with blockade of the PD-1/PD-L1 pathway alone. These results suggest that Tim-3 is involved in the suppression of T cell function during BLV infection.
  • S. Suzuki, S. Konnai, T. Okagawa, N. W. Githaka, E. Kariuki, F. Gakuya, E. Kanduma, T. Shirai, R. Ikebuchi, Y. Ikenaka, M. Ishizuka, S. Murata, K. Ohashi
    INTERNATIONAL JOURNAL OF IMMUNOGENETICS 39 2 170 - 182 2012年04月 [査読有り][通常論文]
     
    The African buffalo (Syncerus caffer) has been implicated as the reservoir of several bovine infectious agents. However, there is insufficient information on the protective immune responses in the African buffalo, particularly in infected animals. In this study, we analysed Th1 cytokines IL-2 and IFN-?, and Th2 cytokines IL-4 and IL-10. The cloned cDNA of IL-2, IL-4, IL-10 and IFN-? contained an open reading frame of 468, 501, 408 and 540 nucleotides, encoding polypeptides of 155, 166, 135 and 179 amino acids, respectively. Nucleotide sequence homology of IL-2, IFN-? and IL-4 was more than 98% between the African buffalo and cattle, which resulted in identical polypeptides. Meanwhile, IL-10 gene of African buffalo and cattle had 95% homology in nucleotide sequence, corresponding to thirteen amino acid residues substitution. Cysteine residues and potential glycosylation sites were conserved within the family Bovinae. Phylogenetic analyses including cytokines of the African buffalo placed them within a cluster comprised mainly of species belonging to the order Artiodactyla, including cattle, water buffalo, sheep, goat, pig and artiodactyl wildlife. A deeper understanding of the structure of these cytokines will shed light on their protective role in the disease-resistant African buffalo in comparison with other closely related species.
  • Tatsuya Shirai, Satoru Konnai, Ryoyo Ikebuchi, Tomohiro Okagawa, Saori Suzuki, Yuji Sunden, Misao Onuma, Shiro Murata, Kazuhiko Ohashi
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY 144 3-4 462 - 467 2011年12月 [査読有り][通常論文]
     
    Lymphocyte activation gene-3 (LAG-3), a major histocompatibility complex (MHC) class II binding CD4 homologue has recently been shown as one of the mechanisms for down-regulating immune responses during chronic disease progression. For the first time, we cloned LAG-3 from two breeds of cattle (Holstein and Japanese Black), and analyzed its expression levels in cattle infected with bovine leukemia virus (BLV), a chronic viral infection that leads to immuno-suppression. The cloned cDNA of bovine LAG-3 have an open reading frame of 1551 nucleotides, encoding a polypeptide of 515 amino acids in length. Similar to the swine LAG-3, the bovine LAG-3 protein sequence consisted of four extracellular domains, a transmembrane domain and an inhibitory motif, KTGELE. We found that the bovine LAG-3 mRNA transcripts were expressed predominantly on T-cells such as CD4(+) and CD8(+) cells, among peripheral blood mononuclear cells. In subsequent expression analysis, LAG-3 mRNA expression on CD4(+) T-cells from BLV-infected cattle was upregulated compared to that in normal cattle. Comparable results were obtained with CD8(+) T-cells from cattle infected with BLV. We further observed strong upregualtion of MHC class II molecule, the ligand for LAG-3 in BLV-infected cattle. These findings indicate an important role for inhibitory receptor molecules such as LAG-3 in chronic bovine infections and future studies will elucidate the specific role of LAG-3 in bovine diseases. (C) 2011 Elsevier B.V. All rights reserved.

その他活動・業績

  • 鈴木紗織, GERI Jacob, GERI Jacob, KNUTSON Steve, BELL-TEMIN Harris, 田村友和, FERNANDEZ David, LOVETT Gabby, LI Beryl, DONG Zhe, TILL Nick, MACMILLAN David W.C., MACMILLAN David W.C., PLOSS Alexander 日本獣医学会学術集会講演要旨集 165th (CD-ROM) 2022年
  • カニクイザルを用いたH5N6亜型高病原性鳥インフルエンザウイルスによる重症肺炎の解析
    伊藤 靖, Nguyen Thanh Cong, 鈴木 紗織, 石垣 宏仁, 仲山 美沙子, 小笠原 一誠 日本病理学会会誌 108 (1) 285 -285 2019年04月 [査読無し][通常論文]
  • H7N9亜型鳥インフルエンザウイルスのノイラミニダーゼ阻害薬耐性変異とその病原性
    鈴木 紗織, 七戸 新太郎, 伊藤 靖, 小笠原 一誠 日本獣医学会学術集会講演要旨集 161回 355 -355 2018年08月 [査読無し][通常論文]
  • 新開大史, 新開大史, 野村直樹, 関屋俊輝, 関屋俊輝, 大野円実, 笹田万友美, 大東卓史, 鈴木紗織, 石垣宏仁, 伊藤靖, 小笠原一誠, 小笠原一誠, 喜田宏, 喜田宏, 喜田宏 日本ワクチン学会学術集会プログラム・抄録集 22nd 99 2018年 [査読無し][通常論文]
  • 山地賢三郎, 安井文彦, 伊藤靖, 鈴木紗織, 本田智子, 山本直樹, 真田崇弘, 石垣宏仁, 石井孝司, 小笠原一誠, 小原道法 日本ワクチン学会学術集会プログラム・抄録集 22nd 118 2018年 [査読無し][通常論文]
  • 伊藤靖, 鈴木紗織, 石垣宏仁, 仲山美沙子, 新開大史, 新開大史, 大東卓史, 野村直樹, 喜田宏, 喜田宏, 喜田宏, 小笠原一誠, 小笠原一誠 日本ワクチン学会学術集会プログラム・抄録集 22nd 99 2018年 [査読無し][通常論文]
  • ノイラミニダーゼ阻害薬耐性H7N9亜型鳥インフルエンザウイルスの薬剤非投与カニクイザルにおける病原性評価
    鈴木 紗織, 七戸 新太郎, 伊藤 靖, 小笠原 一誠 日本獣医学会学術集会講演要旨集 160回 385 -385 2017年08月 [査読無し][通常論文]
  • 東濃篤徳, 鈴木紗織, 森健一, 大出裕高, 松岡和弘, 片貝祐子, 岡林佐知, 槇昇, 岩谷靖雅, 杉浦亙, 明里宏文 霊長類研究 31 (Supplement) 81 -82 2015年06月20日 [査読無し][通常論文]
  • HCVベースのHCV/GBV-Bキメラウイルスはタマリンへ長期感染する
    鈴木紗織, 東濃篤徳, 森健一, 片貝祐子, 槇昇, 明里宏文 第62回日本実験動物学会学術集会 2015年 [査読有り][通常論文]
  • 新世界ザルにおける液性免疫応答の機能低下は霊長類肝炎ウイルスの持続感染に寄与する
    鈴木紗織, 東濃篤徳, 森健一, 大出裕高, 松岡和弘, 岩谷靖雅, 杉浦亙, 片貝祐子, 槇昇, 明里宏文 第31回日本霊長類学会大会 2015年 [査読有り][通常論文]
  • Genetic and immunological escape in persistent GBV-B infection
    Saori Suzuki, Atsunori Higashino, Ken-ichi Mori, Hirotaka Ode, Kazuhiro Matsuoka, Yasumasa Iwatani, Wataru Sugiura, Yuko Katakai, Noboru Maki, Hirofumi Akari 22nd International Symposium on Hepatitis C Virus and Related Viruses 2015年 [査読有り][通常論文]
  • 慢性GBV-B感染におけるenvelope変異および液性免疫からの逃避
    鈴木紗織, 東濃篤徳, 森健一, 大出裕高, 松岡和弘, 岩谷靖雅, 杉浦亙, 片貝祐子, 槇昇, 明里宏文 第63回日本ウイルス学会学術集会 2015年 [査読有り][通常論文]
  • 霊長類ヘパチウイルス慢性感染後寛解におけるウイルスゲノム変異の意義
    東濃篤徳, 鈴木紗織, 大出裕高, 松岡和弘, 森健一, 片貝祐子, 岡林佐知, 槇昇, 岩谷靖雅, 杉浦亙, 明里宏文 第63回日本ウイルス学会学術集会 2015年 [査読有り][通常論文]
  • 横川寛, 中村紀子, 東濃篤徳, 鈴木紗織, 明里宏文, 加藤孝宣, 石井孝司, 脇田隆字 日本ウイルス学会学術集会プログラム・抄録集 62nd 338 2014年10月31日 [査読無し][通常論文]
  • 小型霊長類モデルを用いたヘパチウイルスの持続感染における慢性肝炎発症に影響するウイルスゲノム変異解析
    東濃篤徳, 鈴木紗織, 齊藤暁, 松岡和弘, 大出裕高, 片貝祐子, 岡林佐知, 森健一, 槇昇, 明里宏文 第61回日本実験動物学会総会 2014年 [査読有り][通常論文]
  • Diversity of antiretroviral host factor TRIM5 gene in macaque monkeys
    Akatsuki Saito, Emi E Nakayama, Tatsuo Shioda, Tomoyuki Yoshida, Atsunori Higashino, Saori Suzuki, Yoshi Kawamoto, Hirofumi Akari Cold Spring Harbor meeting on Retroviruses 2013年 [査読有り][通常論文]
  • 急性及び慢性GBV-B感染症における液性免疫の比較解析
    鈴木紗織, 東濃篤徳, 森健一, 吉田友教, 片貝祐子, 齊藤暁, 槇昇, 明里宏文 第61回日本ウイルス学会学術集会 2013年 [査読有り][通常論文]
  • CCR5指向性を示す新規サル指向性HIV-1はサル個体に持続感染する
    齊藤暁, 大附寛幸, 東濃篤徳, 鈴木紗織, 松田健太, 高橋尚史, 松岡佐織, 岩谷靖雅, 杉浦亙, 野間口雅子, 足立昭夫, 保富康宏, 俣野哲朗, 三浦智行, 明里宏文 第61回日本ウイルス学会学術集会 2013年 [査読有り][通常論文]
  • 新世界ザルにおける持続感染GBV-BのQuasispecies解析
    東濃篤徳, 鈴木紗織, 齊藤暁, 片貝祐子, 岡林佐知, 明里宏文 第61回日本ウイルス学会学術集会 2013年 [査読有り][通常論文]
  • The delayed humoral immune responses may be associated with the development of chronic GBV-B infection
    Saori Suzuki, Atsunori Higashino, Ken-ichi Mori, Yuko Katakai, Akatsuki Saito, Noboru Maki, Hirofumi Akari 20th International Symposium on Hepatitis C Virus and Related Viruses 2013年 [査読有り][通常論文]
  • Analysis of dynamics in GB virus B quasispecies in the course of long-term persistent infection and disease progression in marmosets
    Atsunori Higashino, Saori Suzuki, Akatsuki Saito, Yuko Katakai, Sachi Okabayashi, Hirofumi Akari 20th International Symposium on Hepatitis C Virus and Related Viruses 2013年 [査読有り][通常論文]
  • ウイルスの標的細胞指向性はサル指向性HIV-1の増殖に影響するか?
    齊藤暁, 大附寛幸, 東濃篤徳, 鈴木紗織, 松田健太, 高橋尚史, 岩谷靖雅, 杉浦亙, 保富康宏, 俣野哲朗, 三浦智行, 明里宏文 第156回日本獣医学会学術集会 2013年 [査読有り][通常論文]
  • GBV-B感染新世界ザルの液性免疫解析
    鈴木紗織, 東濃篤徳, 森健一, 吉田友教, 齊藤暁, 槇昇, 明里宏文 第60回日本実験動物学会総会 2013年 [査読有り][通常論文]
  • レトロウイルス感受性に影響するマカク属サルTRIM5遺伝子の多様性
    齊藤暁, 中山英美, 塩田達雄, 吉田友教, 東濃篤徳, 鈴木紗織, 川本芳, 明里宏文 第60回日本実験動物学会総会 2013年 [査読有り][通常論文]
  • 霊長類を用いたHCV/ GBV-Bキメラウイルス感染モデル
    東濃篤徳, 森健一, 鈴木紗織, 岩崎優紀, 吉田友教, 齊藤暁, 槇昇, 明里宏文 第60回日本実験動物学会総会 2013年 [査読有り][通常論文]
  • 東濃篤徳, 森健一, 鈴木紗織, 岩崎優紀, 吉田友教, 齊藤暁, 槇昇, 明里宏文 日本ウイルス学会学術集会プログラム・抄録集 60th 413 2012年10月31日 [査読有り][通常論文]
  • 齊藤暁, 河野健, 中山英美, 塩田達雄, 川本芳, 鳥居隆三, 吉田友教, 東濃篤徳, 鈴木紗織, 保富康宏, 明星宏文 日本ウイルス学会学術集会プログラム・抄録集 60th 343 2012年10月31日 [査読有り][通常論文]
  • 岡川朋弘, 今内覚, 池渕良洋, 鈴木紗織, 寸田祐嗣, 村田史郎, 大橋和彦 日本獣医学会学術集会講演要旨集 154th 233 2012年08月31日 [査読無し][通常論文]
  • ウシ難治性疾病に対する多機能型新規治療法の開発
    岡川朋弘, 今内覚, 池渕良洋, 鈴木紗織, 村田史郎, 大橋和彦 動物ワクチン-バイオ医薬品研究会ニュースレター 5 21 -23 2012年06月 [査読無し][招待有り]
  • Theileria parva感染牛属のサイトカイン発現比較解析
    岡川朋弘, 今内覚, Githaka N, 目堅博久, 鈴木紗織, Kariuki E, Skilton R, 石塚真由美, 村田史郎, 大橋和彦 獣医寄生虫学会誌 10 (1-2) 37 2012年03月 [査読無し][通常論文]
  • 今内覚, 池渕良洋, 岡川朋弘, 鈴木紗織, 白井達哉, 村田史郎, 大橋和彦 日本獣医学会学術集会講演要旨集 153rd 117 2012年03月01日 [査読無し][通常論文]
  • An animal model for chimeric virus of hepatitis C virus/GB virus B
    Atsunori Higashino, Ken-ichi Mori, Saori Suzuki, Yuki Iwasaki, Tomoyuki Yoshida, Akatsuki Saito, Noboru Maki, Hirofumi Akari 19th International Symposium on Hepatitis C Virus and Related Viruses 2012年 [査読有り][通常論文]
  • ウシTim-3の発現・機能解析と新規疾病制御法への応用展開
    岡川朋弘, 今内覚, 池渕良洋, 鈴木紗織, 村田史郎, 大橋和彦 動物ワクチン-バイオ医薬品研究会ニュースレター 4 27 -29 2011年12月 [査読無し][招待有り]
  • 岡川朋弘, 今内覚, 池渕良洋, 鈴木紗織, 寸田祐嗣, 村田史郎, 大橋和彦 日本獣医学会学術集会講演要旨集 152nd 224 2011年08月31日 [査読無し][通常論文]
  • 鈴木紗織, 今内覚, 池渕良洋, 岡川朋弘, 寸田祐嗣, 村田史郎, 大橋和彦 日本獣医学会学術集会講演要旨集 152nd 224 2011年08月31日 [査読無し][通常論文]
  • 今内覚, 岡川朋弘, NAFTALY Githaka, 目堅博久, 鈴木紗織, EDWARD Kariuki, ROBERT Skilton, 石塚真由美, 村田史郎, 大橋和彦 日本獣医学会学術集会講演要旨集 152nd 204 2011年08月31日 [査読無し][通常論文]
  • 岡川朋弘, 鈴木紗織, 今内覚, GITHAKA Naftali, KARIUKI Edward, GAKUYA Francis, ESTHER Kanduma, 石塚真由美, 村田史郎, 大橋和彦 日本獣医学会学術集会講演要旨集 150th 212 2010年09月01日 [査読無し][通常論文]

受賞

  • 2022年09月 日本獣医学会 獣医学奨励賞
     鳥インフルエンザ及び牛伝染性リンパ腫ウイルス感染症の病態解析


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.